

# Water Research

## Formulation and probabilistic assessment of reversible biodegradation pathway of Diclofenac in groundwater --Manuscript Draft--

<b>Manuscript Number:</b>	
<b>Article Type:</b>	Research Paper
<b>Keywords:</b>	Diclofenac; denitrification; Reversible biodegradation; Bayesian calibration; Uncertainty quantification; Acceptance-Rejection Sampling
<b>Corresponding Author:</b>	Laura Ceresa, M.D. Politecnico di Milano Milano, ITALY
<b>First Author:</b>	Laura Ceresa
<b>Order of Authors:</b>	Laura Ceresa Alberto Guadagnini Giovanni Michele Porta Monica Riva
<b>Abstract:</b>	<p>We present a conceptual and mathematical framework leading to the development of a biodegradation model capable to interpret the observed reversibility of the Pharmaceutical Sodium Diclofenac along its biological degradation pathway in groundwater. Diclofenac occurrence in water bodies poses major concerns due to its persistent (and bioactive) nature and its detection in surface waters and aquifer systems. Despite some evidences of its biodegradability at given reducing conditions, Diclofenac attenuation is often interpreted with models which are too streamlined, thus potentially hampering appropriate quantification of its fate. In this context, we propose a modeling framework based on the conceptualization of the molecular mechanisms of Diclofenac biodegradation which we then embed in a stochastic context, thus enabling one to quantify predictive uncertainty. We consider reference environmental conditions (biotic and denitrifying) associated with a set of batch experiments that evidence the occurrence of a reversible biotransformation pathway, a feature that is fully captured by our model. The latter is then calibrated in the context of a Bayesian modeling framework through an Acceptance-Rejection Sampling approach. By doing so, we quantify the uncertainty associated with model parameters and predicted Diclofenac concentrations. We discuss the probabilistic nature of uncertain model parameters and the challenges posed by their calibration with the available data. Our results are consistent with the recalcitrant behavior exhibited by Diclofenac in groundwater and documented through experimental data and support the observation that unbiased estimates of the hazard posed by Diclofenac to water resources should be assessed through a modeling strategy which fully embeds uncertainty quantification.</p>
<b>Suggested Reviewers:</b>	<p>Bill X. Hu Jinan University Institute of Groundwater and Earth Sciences 2776090374@qq.com Expertise in Stochastic Hydrogeology, Karst Hydrology and Seawater intrusion to groundwater.</p> <p>Xavier Sanchez-Vila Universitat Politecnica de Catalunya xavier.sanchez-vila@upc.edu Expertise in quantitative groundwater hydrology</p> <p>Ishai Dror Weizmann Institute of Science ishai.dror@weizmann.ac.il Expertise in Environmental Impact Assessment</p> <p>Tiziana Tosco Politecnico di Torino</p>

# Formulation and probabilistic assessment of reversible biodegradation pathway of Diclofenac in groundwater

Laura Ceresa, Alberto Guadagnini, Giovanni M. Porta, Monica Riva

*Department of Civil and Environmental Engineering (DICA), Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milano, Italy*

---

## Abstract

We present a conceptual and mathematical framework leading to the development of a biodegradation model capable to interpret the observed reversibility of the Pharmaceutical Sodium Diclofenac along its biological degradation pathway in groundwater. Diclofenac occurrence in water bodies poses major concerns due to its persistent (and bioactive) nature and its detection in surface waters and aquifer systems. Despite some evidences of its biodegradability at given reducing conditions, Diclofenac attenuation is often interpreted with models which are too streamlined, thus potentially hampering appropriate quantification of its fate. In this context, we propose a modeling framework based on the conceptualization of the molecular mechanisms of Diclofenac biodegradation which we then embed in a stochastic context, thus enabling one to quantify predictive uncertainty. We consider reference environmental conditions (biotic and denitrifying) associated with a set of batch experiments that evidence the occurrence of a reversible biotransformation pathway, a feature that is fully captured by our model. The latter is then calibrated in the context of a *Bayesian* modeling framework through an Acceptance-Rejection Sampling approach. By doing so, we quantify the uncertainty associated with model parameters and predicted Diclofenac concentrations. We discuss the probabilistic nature of uncertain model parameters and the challenges posed by their calibration with the available data.

---

\*Corresponding author

*Email address:* [laura.ceresa@polimi.it](mailto:laura.ceresa@polimi.it) (Laura Ceresa)

Our results are consistent with the recalcitrant behavior exhibited by Diclofenac in groundwater and documented through experimental data and support the observation that unbiased estimates of the hazard posed by Diclofenac to water resources should be assessed through a modeling strategy which fully embeds uncertainty quantification.

*Key words:* Diclofenac, Denitrification, Reversible biodegradation, Bayesian calibration, Uncertainty quantification, Acceptance-Rejection Sampling

---

## 1 **1. Introduction**

2 Groundwater contamination by pharmaceuticals (PhAs) stands as a critical  
3 issue in modern society. Regulating authorities are recognizing potential  
4 risks associated with pollution of drinking water sources by biologically  
5 active compounds, such as PhAs, even as their detection is often limited to  
6 trace concentration levels ( $1 - 1000[ng \cdot L^{-1}]$ ). Several classes of medical drugs  
7 are currently monitored according to international guidelines (CHMP, E.M.A.  
8 (2006)), with particular focus on the most persistent compounds. Sodium  
9 Diclofenac (NaDcf) ( $NaDcf_{(s)}$ ,  $C_{14}H_{10}Cl_2NO_2 \cdot Na_{(s)}$ , CAS number 15307-79-6,  
10  $MW = 318.3[g \cdot mol^{-1}]$ , Figure A.1 (a) in Appendix A) (Fonger et al. (2014)),  
11 a Non-Steroidal Anti-Inflammatory Drug (NSAID) is commonly prescribed as  
12 an analgesic (Small (1989)) and is seen to pose major concerns to surface  
13 waters and groundwater bodies (Lonappan et al. (2016)). Due to its suspected  
14 long-term impact on the ecology of aquatic environments upon chronic  
15 exposure, NaDcf has been classified by the Global Water Research Coalition  
16 (GWRC) as *Class 1* – high priority substance within relevant Pharmaceuticals  
17 to the water cycle (de Voogt et al. (2007)). Despite risk assessment protocols  
18 (CHMP, E.M.A. (2006)) often address Sodium Diclofenac biodegradation  
19 to non-hazardous compounds as a natural attenuation mechanism, several authors  
20 have recently questioned its effectiveness under reducing redox conditions,  
21 such as, e.g., denitrifying scenarios (Barbieri et al. (2012), Chiron and Duwig  
22 (2016)). While studies based on laboratory-scale batch systems (Barbieri et al.

(2011)), column experiments (Schaffer et al. (2015)) as well as field-scale data (Nham et al. (2015), Chiron and Duwig (2016)) are available in the literature, there is still a lack of knowledge about the behavior of Diclofenac (Dcf) in groundwater bodies, especially under scenarios comprising the occurrence of biologically mediated transformations. This observation suggests the need to further enhance *state-of-the-art* modeling frameworks and tools to support policies associated with environmental protection of aquatic compartments from risks related to bioaccumulation and biomagnification (CHMP, E.M.A. (2006)). In this context, it is noted that oversimplified biochemical models might lead to an inaccurate assessment of contaminant fate (Greskowiak et al. (2017)). Otherwise, relevant uncertainties might arise as a consequence of the complexity and non-linearity of model input-output relationships which can be associated with the representation of the richness of molecular dynamics associated with a full chemical reaction network that might in turn require a high level of model parametrization (Porta et al. (2018)). These uncertainties are hard to control and eventually constrain and reduce because of the paucity of available datasets documenting the fate of emerging contaminants and pharmaceuticals in groundwater. Therefore, implementation of an appropriate stochastic inverse modeling framework is key to address the effects of uncertainty propagation from the model structure and parameters to target model outputs (e.g., contaminant concentrations in environmental compartments), as a consequence of conditioning modeling results on available observations.

In this work, we focus on the fate of Diclofenac in groundwater under biotic, denitrifying redox conditions. These environmental conditions are relevant in field scale scenarios such as those that can take place across regions downstream of reactive barriers installed in the hyporheic zone. Such a scenario has been mimicked in a series of (biotic) *batch* experiments (Barbieri et al. (2012), their series  $1[\mu\text{g} \cdot \text{L}^{-1}]$ ), which document the emergence of 5-C-Nitro-Diclofenac ( $\text{NO}_2\text{Dcf}$ ) derivative ( $\text{NO}_2\text{Dcf}_{(\text{aq})}$ ),  $\text{C}_{14}\text{H}_{10}\text{Cl}_2\text{N}_2\text{O}_{4(\text{aq})}$ ,  $MW = 341.15[\text{g} \cdot \text{mol}^{-1}]$ , Figure A.2 (b) in Appendix A) and its reversible back-transformation into the parent compound once denitrifying conditions cease to occur. Several authors (Bar-

54 bieri et al. (2012), Chiron and Duwig (2016)) document the reversibility  
55 of Diclofenac transformation processes along its biologically mediated reaction  
56 pathway (under the above mentioned environmental conditions), which involves  
57 an almost complete back-transformation of its by-products into the parent com-  
58 pound. The latter process takes place upon complete Nitrite depletion, which  
59 is turn marked by the the occurrence of stronger reducing conditions than deni-  
60 trification (such as, e.g., those corresponding to  $\text{Mn}_{(s)}^{4+}/\text{Mn}_{(aq)}^{2+}$  in our scenario),  
61 and is supported by experimental observations (Barbieri et al. (2012), Chiron  
62 and Duwig (2016)).

63 Our study is keyed to the following three major objectives: (i) the develop-  
64 ment of a model capable of interpreting the observed reversible pathway of  
65 Diclofenac; (ii) the design of a workflow for the stochastic calibration of such a  
66 model through the estimation of its parameters against observations; and (iii)  
67 the interpretation of model parameters and outputs in a probabilistic sense,  
68 which fully embeds predictive uncertainty quantification. To achieve these ob-  
69 jectives, we consider the set of previously mentioned microcosms experiments  
70 (Barbieri et al. (2011) and Barbieri et al. (2012)) that document the reversible  
71 behavior of the tranformation products (TPs) of Diclofenac and Sulphamethox-  
72 azole (SMX) downstream of the denitrification cycle, as discussed above. To  
73 interpret the selected dataset, we first formulate an original conceptual and  
74 biochemical model, which follows the same rationale employed in Rodríguez-  
75 Escalas and Sanchez-Vila (2016) to model the fate of SMX, another amino  
76 compound used as antibiotic. Our stochastic inverse modeling approach relies  
77 on a *Bayesian* framework and rests on Acceptance-Rejection Sampling (ARS)  
78 technique to provide a probabilistic characterization of model parameters based  
79 on available data.

## 80 **2. Methods**

81 We first introduce the geochemical model we consider to interpret the doc-  
82 umented reversible biodegradation pathway of Diclofenac. The key elements of

83 the implemented model are offered in Section 2.1. Additional details about the  
84 implementation strategy within the geochemical simulation Software used (pH  
85 RedOx Equilibrium C++ Software (PHREEQC), version 3.6.2, Parkhurst and  
86 Appelo (2013)) are provided in Supplementary Material S1. Further elements  
87 on the experimental framework of reference (Barbieri et al. (2012), Rodríguez-  
88 Escalas and Sanchez-Vila (2016)) are available in the Supplementary Material  
89 S2. Section 2.2 describes the stochastic framework employed to calibrate the  
90 proposed model and characterize associated parameters and relevant outputs,  
91 including quantification of predictive uncertainty. Within the suite of *Bayesian*  
92 inverse modeling techniques, we rely on Acceptance-Rejection Sampling due to  
93 its unbiased nature. This approach yields the posterior (i.e., conditional on  
94 available data) probability distribution of uncertain model parameters within a  
95 *Bayesian* framework, circumventing the assumption of Gaussianity typical of,  
96 e.g., a Maximum Likelihood (ML) framework.

### 97 *2.1. Geochemical model*

98 We model the combined action of several mechanisms that can impact the  
99 temporal evolution of Diclofenac concentrations, i.e., precipitation/dissolution  
100 (see Supplementing Material S1.2.1), sorption/desorption to soil particles (see  
101 Supplementing Material S1.2.2), and biodegradation (a term which is here em-  
102 ployed to embed several mechanisms that are discussed in details in Section  
103 2.1.1). We illustrate here some details of the biochemical model employed to  
104 characterize biodegradation of Diclofenac. The full description of the model,  
105 including the complete collection of the considered chemical reactions is then  
106 provided in the Supplementary Materials and Appendices.

#### 107 *2.1.1. Reversible biodegradation pathway*

108 Our model aims at interpreting the fate of Diclofenac at the environmen-  
109 tal conditions investigated in Barbieri et al. (2012). We conceptualize the  
110 biochemical process according to the three Phases described in the following.  
111 These are schematically depicted in Figure 1 and further detailed in Figure 2.




Figure 1: Reversible degradation pathway of Diclofenac under biotic, denitrifying redox conditions. Chemical processes leading to the release of transformation products are framed within specific phases, here denoted as Phase (I), (II), and (III). Main uncertain model parameters are also depicted within boxes (blue and green backgrounds of these denote whether the corresponding reactions are framed in the context of bacterial metabolism or not, respectively).




Figure 2: Reaction network of Diclofenac reversible biodegradation.



- 112 • (Phase *I*) The abiotic degradation of HDcf<sub>(aq)</sub> to N-Nitroso-Diclofenac  
113 (NODcf) (i.e., NODcf<sub>(aq)</sub>, C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3(aq)</sub>; see Figure A.2 (a) in Ap-  
114 pendix A) takes place through *co-metabolism* under anoxic, biotic deni-  
115 trifying redox conditions. Here, Diclofenac does not participate directly  
116 to the metabolic mechanism, which involves the (kinetically controlled)  
117 microbial reduction of Nitrate N(V) (NO<sub>3(aq)</sub><sup>-</sup>) along the Nitrogen reduc-  
118 tion cycle. This yields elemental Nitrogen N(0) (N<sub>2(g)</sub>) upon complete  
119 conversion of Nitrite N(III)(NO<sub>2(aq)</sub><sup>-</sup>), a metastable intermediate product  
120 typically observed along the N(V) reduction cycle (Appelo and Postma  
121 (2004)). The process is sustained by the oxidation of dissolved organic  
122 matter (*C<sub>ORG</sub>*) to Carbon dioxide C(IV) (CO<sub>2(aq)</sub>). N-nitrosation of HDcf  
123 takes place together with aqueous complexation of Nitrite into Nitrous  
124 acid (HNO<sub>2(aq)</sub>), a process that can be considered at instantaneous equi-  
125 librium and is characterized by p*K<sub>a</sub>* of approximately 3.2 (Fonger et al.  
126 (2014)). The key role of Nitrous acid in this Phase is consistent with  
127 the guidelines of environmental geochemistry, which identify HNO<sub>2(aq)</sub> as  
128 a typical nitrosating agent at relevant (prevalently alkaline) environmen-  
129 tal conditions (Stumm and Morgan (2012)). In this context, Diclofenac  
130 degradation is *abiotic* and *co-metabolic* because the compound does not  
131 participate directly to the redox metabolism of denitrification.
- 132 • (Phase *II*) The second Phase involves the evolution of NODcf to NO<sub>2</sub>Dcf.  
133 We note that N-Nitroso-Diclofenac is typically considered an unstable in-  
134 termediate product that rapidly evolves at appropriate reducing condi-  
135 tions (Smith (2020), Chiron and Duwig (2016)), such as those associ-  
136 ated with, e.g., the presence of Pyrolusite (MnO<sub>2(s)</sub>) acting as oxidizer.  
137 Here, Nitrites NO<sub>2(aq)</sub><sup>-</sup> simultaneously act as attacking reagents and Lewis  
138 base catalysts of the electrophilic aromatic substitution (EAS) yielding  
139 5-C-Nitro-Diclofenac, which corresponds to the final TP experimentally  
140 detected by several authors (Barbieri et al. (2012), Chiron and Duwig  
141 (2016)) under denitrifying redox conditions. This process takes place

142 jointly with denitrification and is modeled as a multistage reaction. The  
 143 involved steps are consistent with previous studies (Chiron and Duwig  
 144 (2016)) and are here interpreted through a kinetic model. In this context,  
 145 the evolution of NODcf is initiated by its one-electron oxidation sustained  
 146 by Pyrolusite reduction. The latter yields N-Nitroso-Dcf<sup>+</sup> (Lewis for-  
 147 mula NODcf<sup>+</sup><sub>(aq)</sub>), a nitroso radical cation of NODcf which features a  
 148 positive charge localized on the central Nitrogen of the amino functional  
 149 group (Figure A.3 (a) in Appendix A). This is a highly unstable compound  
 150 which undergoes a spontaneous fragmentation into Nitrous monoxide free  
 151 radical ( $\bullet$ NO) and Nitrenium cation, here denoted as Dcf<sup>+</sup> (see Figure A.3  
 152 (b) in Appendix A). Consistent with the resonance theory (Smith (2020)),  
 153 an instantaneous rearrangement of the positive charge is expected at this  
 154 step (the shift occurring from the central Nitrogen of the amino functional  
 155 group towards the topping ring). This yields the carbocation depicted in  
 156 Figure A.3 (c) of Appendix A, a typical electrophile that can easily be  
 157 neutralized by nucleophiles such as NO<sub>2</sub><sup>-</sup><sub>(aq)</sub>, consistent with the Lewis  
 158 theory on acid-base reactions. Specifically, the reaction product is here a  
 159 structural isomer (termed NO<sub>2</sub>Dcf<sub>ISO2(aq)</sub>; see Figure A.4 (a) of Appendix  
 160 A) of the detected TP, 5-C-Nitro-Diclofenac. The last stage of Phase (II)  
 161 involves instantaneous conversion of NO<sub>2</sub>Dcf<sub>ISO2(aq)</sub> to the main isomer  
 162 NO<sub>2</sub>Dcf<sub>(aq)</sub>. This occurs through simultaneous protonation of the double  
 163 C=N bond of the amino group and one-proton removal in the *para* position  
 164 of the topping ring, which takes place through the action of a strong Lewis  
 165 base, possibly NO<sub>2</sub><sup>-</sup><sub>(aq)</sub>. The ring aromaticity is then restored, yielding the  
 166 expected NO<sub>2</sub>Dcf derivative (Figures A.2 (b) and A.4 (b) in Appendix A).

- 167 • (Phase (III)) The last Phase involves two consecutive reactions. First, we  
 168 consider NO<sub>2</sub>Dcf<sub>(aq)</sub> to undergo a reductive transformation to the corre-  
 169 sponding amine 5-Aminyl-Diclofenac (NH<sub>2</sub>Dcf) (C<sub>14</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>(aq)</sub>, Fig-  
 170 ure A.2 (c) of Appendix A), consistent with previous studies on aquatic  
 171 chemistry (Stumm and Morgan (2012)). Here, NH<sub>2</sub>Dcf<sub>(aq)</sub> acts as a

172 meta-stable intermediate in the broader context of back-transformation  
173 processes to the parent compound. Consistent with Appelo and Postma  
174 (2004), a *direct* microbial transformation of 5-C-Nitro-Diclofenac takes  
175 place at this step, sustained by additional oxidation of organic Carbon.  
176 The second reaction of Phase (*III*) involves  $\text{NH}_2\text{Dcf}$  back-transformation  
177 to the parent compound through electrophilic aromatic substitution. In  
178 our approach we assume that dissolved protons  $\text{H}_{(\text{aq})}^+$  are responsible for  
179 protonation of  $\text{NH}_2\text{Dcf}$ , which is known to act as rate limiting step in  
180 the context of electrophilic aromatic substitutions. This yields a carbo-  
181 cation (termed  $\text{NH}_3\text{Dcf}_{(\text{aq})}^+$ ; see Figure A.5 (a) of Appendix A) whose  
182 aminyl group  $\text{NH}_2^+_{(\text{aq})}$  is removed by the action of strong bases, possibly  
183 dissolved hydroxyl anions  $\text{OH}^-_{(\text{aq})}$ . The final product is then the parent  
184 compound  $\text{HDcf}_{(\text{aq})}$ , which is finally restored together with Hydroxylamine  
185  $\text{NH}_2\text{OH}_{(\text{aq})}$  (Figure A.5 (b) in Appendix A), the secondary product of this  
186 reaction.

### 187 2.1.2. Quantitative model description

188 This Section is devoted to the illustration of the main details about the  
189 conceptual framework and the ensuing formulation of the mathematical model  
190 employed to interpret the reversible biochemical pathway introduced in Section  
191 2.1.1. Consistent with the mixture used in the microcosms experiments of Bar-  
192 bieri et al. (2011) and with the formulations in Rodríguez-Escales and Sanchez-  
193 Vila (2016) (see the Supplementary material S1.1.1 for details), organic matter  
194 at Phase (*I*) is modeled as a mixture of Methanol C(-II) ( $\text{CH}_4\text{O}_{(\text{aq})}$ ) and Acetate  
195 anion C(0) ( $\text{C}_2\text{H}_3\text{O}_2^-_{(\text{aq})}$ ). For completeness, we recall that Rodríguez-Escales  
196 and Sanchez-Vila (2016) model the reaction rate of denitrification (per unit  
197 mole consumption of organic Carbon) according to the following *Multiplicative*



198 *Monod* equations (Appelo and Postma (2004)):

$$\begin{aligned}
199 \quad RR_{C_{ORG}}^{(REDOX1)}(t) &= - \left. \frac{d\{C_{ORG}(aq)\}(t)}{dt} \right|_{(REDOX1)} \\
200 \quad &= r_{max1} \frac{\{C_{ORG}(aq)\}(t)}{\{C_{ORG}(aq)\}(t) + K_{half1}^{C_{ORG}}} \frac{\{NO_3^-(aq)\}(t)}{\{NO_3^-(aq)\}(t) + K_{half}^{NO_3^-}} \\
201 \quad &\quad \cdot \{CH_2O(s)\} \quad (1)
\end{aligned}$$


$$\begin{aligned}
202 \quad RR_{C_{ORG}}^{(REDOX2)}(t) &= - \left. \frac{d\{C_{ORG}(aq)\}(t)}{dt} \right|_{(REDOX2)} = \\
203 \quad &= r_{max2} \frac{\{C_{ORG}(aq)\}(t)}{\{C_{ORG}(aq)\}(t) + K_{half2}^{C_{ORG}}} \frac{\{NO_2^-(aq)\}(t)}{\{NO_2^-(aq)\}(t) + K_{half}^{NO_2^-}} \\
204 \quad &\quad \cdot \frac{K_{inhib}}{\{NO_3^-(aq)\}(t) + K_{inhib}} \{CH_2O(s)\} \quad (2)
\end{aligned}$$

206 where  $CH_2O(s)$  is the biomass molarity,  $r_{max_i}$ ,  $i = 1, 2$  is the maximum rate  
207 of substrate consumption relative to biomass in the  $i - th$  redox reaction,  
208  $K_{half_i}$ ,  $i = C_{ORG1}, C_{ORG2}, NO_3^-, NO_2^-$  are half saturation constants, and the  
209 inhibition constant  $K_{inhib}$  embeds the hindering effect of Nitrates on Nitrites  
210 reduction. The notation  $\{\cdot\}$  identifies species activity, that tends to coincide  
211 with molar concentration in very diluted solutions (Appelo and Postma (2004)).  
212 Note that these parameters are not subject to calibration in our work, being  
213 rather fixed to the values estimated by Rodríguez-Escales and Sanchez-Vila  
214 (2016) (Table 2 in Section 2.2).

215 Diclofenac nitrosation takes place together with aqueous complexation into Ni-  
216 trous acid, according to the following stages (Mirvish (1975)): (a) first, two  
217 moles of Nitrous acid rapidly dissociate in the nitrosyl carrier  $NO_2 \cdot NO$  (Nitrous  
218 anhydride) and water; then, (b)  $NO_2 \cdot NO$  reacts with the secondary amine, yield-  
219 ing N-Nitroso-Diclofenac (rate limiting step):



223 The global stoichiometry is:






226 Diclofenac nitrosation is therefore characterized by a reaction rate of order two  
 227 with respect to Nitrous acid concentration and of order three globally, i.e.,:

$$\begin{aligned}
 228 \quad RR_{NODcf}(t) &= \frac{d\{\text{NODcf}(\text{aq})\}(t)}{dt} = k\{\text{HDcf}(\text{aq})\}(t)\{\text{NO}_2\cdot\text{NO}\} \\
 229 \quad &= k\{\text{HDcf}(\text{aq})\}(t)K_{eq1}\{\text{HNO}_2(\text{aq})\}^2(t) \\
 230 \quad &= k_1\{\text{HDcf}(\text{aq})\}(t)\{\text{HNO}_2(\text{aq})\}^2(t) \quad (6) \\
 231
 \end{aligned}$$


232 where  $k_1 = kK_{eq1}$  is a rate constant. For simplicity, we neglect here the tem-  
 233 poral evolution of biomass concentration, which is set to the same value as in  
 234 Rodríguez-Escales and Sanchez-Vila (2016).

235 Phase (II) is modeled assuming that one-electron oxidation of HDcf is gov-  
 236 erned by redox equilibria, the reductive half-reaction involving the redox couple  
 237  $\text{MnO}_{2(\text{s})}/\text{Mn}_{2(\text{aq})}^+$ . The spontaneous fragmentation yielding Nitrenium cations is  
 238 then considered instantaneous, consistent with the high instability of the latter.  
 239 The nucleophilic attack of Nitrite to the carbocation is then rate limiting, in  
 240 agreement with the chemistry of Lewis acid-base reactions (Smith (2020)) and  
 241 also consistent with the presence of a substituted amino group ( $-\text{NHC}_6\text{H}_3\text{Cl}_2$ )  
 242 on the top (aromatic) ring, which is *para* activating towards further substitution  
 243 (on the very same ring). Lastly, the central Nitrogen protonation in the amino  
 244 group (taking place after neutralization of the positive charge by  $\text{NO}_2^-(\text{aq})$  attack  
 245 to the carbocation) is again instantaneous.

246 These steps can be expressed as:



253 Thus, the global stoichiometry becomes:




257 The global reaction rate can be formulated as:

$$\begin{aligned}
 258 \quad & RR_{\text{NO}_2\text{Dcf}}(t) = \frac{d\{\text{NO}_2\text{Dcf}_{(\text{aq})}\}(t)}{dt} = k\{\text{NO}_{2(\text{aq})}^-\}(t)\{\text{Dcf}^+(\text{aq})\}(t) \\
 259 \quad & = k_2 \frac{\{\text{NO}_{2(\text{aq})}^-\}(t)\{\text{H}^+(\text{aq})\}^2(t)\{\text{NODcf}_{(\text{aq})}\}(t)}{\sqrt{\{\text{Mn}^{2+}_{(\text{aq})}\}(t)}} \quad (12) \\
 260 \quad &
 \end{aligned}$$

261 where  $k_2 = k \cdot K_{redox}$  is the process rate constant.

262 The back-transformation into the parent compound (Phase *(III)*) entails two  
 263 consecutive reactions. The first one involves the direct metabolic transformation  
 264 of  $\text{NO}_2\text{Dcf}$  into  $\text{NH}_2\text{Dcf}$  (corresponding to microbial reduction sustained by or-  
 265 ganic Carbon oxidation) whose kinetics are modeled according to the *Michaelis-*  
 266 *Menten-Monod* mathematical framework (Appelo and Postma (2004)) (specif-  
 267 ically, through the *Multiplicative Monod* equations). The global stoichiometry  
 268 (see Supplementary Material S1.1.1) can be expressed as:





272 This reaction involves reduction of the nitro group to aromatic amine through  
 273 a six-electron transfer mechanism, in agreement with Razo-Flores et al. (1997)  
 274 and Kulkarni and Chaudhari (2007). Note that the Methanol/Acetate mixture  
 275 representing organic matter can be modeled through a single molecule of organic  
 276 Carbon ( $C_{ORG}$ ), the latter being implemented in PHREEQC as  $\text{CH}_{2.5}\text{O}^{-0.3}$   
 277 (further details are then available in Supplementary Material S1.1.1).


278 The second stage involves the EAS of the aminyl group in  $\text{NH}_2\text{Dcf}$ . Here,  
 279 the protonation step is rate limiting, in agreement with Smith (2020). The  
 280 subsequent withdrawal of aminyl groups by dissolved hydroxyl anions is typically

281 very fast and is then considered to take place instantaneously.

282 This second reaction is then described by the following stages:



286 This leads to the following global stoichiometry:



289 where  $\text{NH}_2\text{OH}_{(\text{aq})}$  (Figure A.5 in Appendix A) represents Hydroxylamine, which  
 290 is another TP for which experimental investigations are still very scarce for the  
 291 purposes of our study (i.e., it has not been monitored in the experiments of  
 292 Barbieri et al. (2012)).

293 The corresponding reaction rates are rendered as:

$$294 \quad RR_{\text{NH}_2\text{Dcf}}(t) = \frac{d\{\text{NH}_2\text{Dcf}(\text{aq})\}(t)}{dt}$$

$$295 \quad = r_{max3} \frac{\{\text{C}_{\text{ORG}}(\text{aq})\}(t)}{\{\text{C}_{\text{ORG}}(\text{aq})\}(t) + K_{half3}^{\text{C}_{\text{ORG}}}} \frac{\{\text{NO}_2\text{Dcf}(\text{aq})\}(t)}{\{\text{NO}_2\text{Dcf}(\text{aq})\}(t) + K_{half}^{\text{NO}_2\text{Dcf}}}$$

$$296 \quad \frac{K_{inhib2}}{\{\text{NO}_2^-(\text{aq})\}(t) + K_{inhib2}} \{\text{CH}_2\text{O}(\text{s})\} \quad (17)$$

$$297 \quad RR_{\text{BT}}(t) = -\frac{d\{\text{NH}_2\text{Dcf}(\text{aq})\}(t)}{dt} = \frac{d\{\text{HDcf}(\text{aq})\}(t)}{dt}$$

$$298 \quad = k_3 \{\text{H}^+(\text{aq})\} \{\text{NH}_2\text{Dcf}(\text{aq})\} \quad (18)$$

300 Here,  $r_{max3}$  is the maximum *Michaelis-Menten-Monod* rate;  $K_{half3}^{\text{C}_{\text{ORG}}}$ ,  $K_{half}^{\text{NO}_2\text{Dcf}}$ ,  
 301 and  $k_{inhib2}$  are half-saturation and inhibition constants; and  $k_3$  is the rate con-  
 302 stant of the last reaction of Phase (III). Note that equation (17) considers  
 303 inhibition on the reduction of nitroaromatics in the presence of higher-priority  
 304 oxidizers, such as Nitrites, which are associated with lower standard potentials  
 305 of reduction (see, e.g., Appelo and Postma (2004)).


306 The chemical model is completed by three additional processes, which are con-  
 307 sidered at chemical equilibrium: (i) Diclofenac acid adsorption to soil particles,  
 308 (ii) dissolution of Sodium Diclofenac in water, and (iii) dissociation of all of the  
 309 (relevant) acidic compounds present in solution (i.e., Nitric and Nitrous acids,

310 Carbonic acid, HDcf and organic matter, as partially derived from the Acetic  
 311 acid). Sorption is modeled as solely due to surface complexation of the neu-  
 312 tral Diclofenac acid onto the organic Carbon fraction of the soil, the anionic  
 313 form being insensitive to adsorptive mechanisms at the environmental condi-  
 314 tions considered (Appelo and Postma (2004)). Surface complexation of HDcf is  
 315 associated with a linear distribution coefficient (consistent with the very diluted  
 316 conditions of the aqueous solution analyzed), defined as:

$$317 \quad k_d = \frac{\{\text{HDcf}_{(ADSORBED)}\}}{\{\text{HDcf}_{(aq)}\}} \quad (19)$$

319 Considering a linear isotherm approach and following the procedure detailed in  
 320 the Supplementary Material S1.2.1, we obtain  $k_d \approx 3.6 \cdot 10^{-3} [L/kg_{sed}]$ , clearly  
 321 evidencing the negligible impact of sorption to the extent of Diclofenac degra-  
 322 dation (additional details are provided in the above mentioned Supplementary  
 323 Material).

324 The dissolution of Sodium Diclofenac is then modeled as:



$$328 \quad k_{eq} = \frac{\{\text{Na}^+_{(aq)}\}\{\text{Dcf}^-_{(aq)}\}}{\{\text{NaDcf}_{(s)}\}} = \frac{k_s}{\{\text{NaDcf}_{(s)}\}} = k_s \quad (21)$$

330 where  $k_s = 2.3 \cdot 10^{-10} [mol^2 \cdot L^{-2}]$  represents the solubility constant of the  
 331 salt, as inferred from available databases (Wishart et al. (2006)). Further  
 332 details are provided in Supplementary Material S1.2.1, where we show that  
 333 one could consider in principle the full amount of NaDcf as fully dissolved in  
 334 solution, consistent with the value of the solubility product and the limited  
 335 (trace) concentration levels at which Sodium Diclofenac is typically detected in  
 336 groundwater.

337 We finally note that acid dissociation processes govern the degree of ionization  
 338 of the molecules (water speciation). In this context, dissociation of Diclofenac  
 339 acid and organic matter (the same rationale applying for other molecules of



340 interest) can be formulated as (Wishart et al. (2006)):

$$341 \quad \text{HDcf}_{(\text{aq})} \xrightleftharpoons[1/K_a]{K_a} \text{H}_{(\text{aq})}^+ + \text{Dcf}_{(\text{aq})}^- \quad (22)$$

$$342 \quad \text{p}K_a = -\text{Log}_{10}K_a = -\text{Log}_{10}\left\{\frac{\{\text{H}_{(\text{aq})}^+\}\{\text{Dcf}_{(\text{aq})}^-\}}{\{\text{HDcf}_{(\text{aq})}\}}\right\} \approx 4.2 \quad (23)$$

$$343 \quad \frac{3}{10}\text{C}_2\text{H}_3\text{O}_2^-_{(\text{aq})} + \frac{2}{5}\text{CH}_4\text{O}_{(\text{aq})} \xrightleftharpoons[1/K_a]{K_a} \frac{3}{10}\text{C}_2\text{H}_4\text{O}_2_{(\text{aq})} + \frac{2}{5}\text{CH}_3\text{O}^-_{(\text{aq})} \frac{1}{10}\text{H}_{(\text{aq})}^+ \quad (24)$$

$$344 \quad \text{p}K_a = -\text{Log}_{10}K_a = \frac{\{\text{C}_2\text{H}_4\text{O}_2_{(\text{aq})}\}^{0.3} \cdot \{\text{CH}_3\text{O}^-_{(\text{aq})}\}^{0.4} \cdot \{\text{H}_{(\text{aq})}^+\}^{0.1}}{\{\text{C}_2\text{H}_3\text{O}_2^-_{(\text{aq})}\}^{0.3} + \{\text{CH}_4\text{O}_{(\text{aq})}\}^{0.4}} = -4.772 \quad (25)$$

345

346 Our implementation fully includes also this latter process, additional details be-  
 347 ing available in Supplementary Materials S1.2.1 and S1.2.3 for Dcf and organic  
 348 matter, respectively.

349 We also note that in our study the temporal evolution of Diclofenac concentra-  
 350 tions always refers to the *total* molarity of Dcf *master* species (Parkhurst and  
 351 Appelo (2013)), i.e., the overall contribution of its anionic and undissociated  
 352 forms.

## 353 2.2. Stochastic model calibration

354 The mathematical representation of the biochemical setting we consider is  
 355 rendered through the system of equations (1), (2), (6), (12), (17), (18), (19),  
 356 (21), (23) and (25). This formulation is here applied under the prescribed initial  
 357 conditions illustrated in the Supplementary Material S2 to interpret the data  
 358 listed in Table 3. Stochastic model calibration is here performed upon consid-  
 359 ering the seven model parameters listed in Table 1 as uncertain, the remaining  
 360 model parameters (listed in Table 2) being assumed as known, on the basis of  
 361 prior studies (Rodríguez-Escales and Sanchez-Vila (2016)).

362 Our uncertainty analysis is framed in the context of *Bayesian* model calibration,  
 363 which is performed through Acceptance-Rejection Sampling. In the absence of  
 364 additional information about possible ranges of variability of the model param-  
 365 eters, the latter are obtained starting from a preliminary fit against the available

366 data. This step involves obtaining preliminary estimates of uncertain model  
 367 parameters through a satisfactory visual agreement between experimental data  
 368 and simulation results. The parameter support is then assessed upon considering  
 369 two logarithmic cycles centered around these preliminary estimates. The uncer-  
 370 tain parameters are then considered as independent and identically distributed  
 371 (*iid*) random variables, each characterized by a uniform distribution within the  
 372 intervals listed in Table 1. The choice of the latter distribution enables one  
 373 to give the same weight to all parameter values across their support. Random  
 374 sampling of parameter values within the corresponding support is performed  
 through a classical Quasi-Monte Carlo technique (Sobol (1998)). Practical

Uncertain parameter	Lower limit	Upper limit
$k_1[\frac{L^2}{mol^2 \cdot s}]$	$1.2 \cdot 10^8$	$1.2 \cdot 10^{10}$
$k_2[\frac{L^{0.4}}{mol^{0.4} \cdot s}]$	$1.3 \cdot 10^2$	$1.3 \cdot 10^4$
$r_{max3}[\frac{1}{s}]$	$5.0 \cdot 10^{-12}$	$5.0 \cdot 10^{-10}$
$K_{half3}^{CORG}[M]$	$1.0 \cdot 10^{-7}$	$1.0 \cdot 10^{-5}$
$K_{half}^{NO_2^{Dcf}}[M]$	$7.0 \cdot 10^{-10}$	$7.0 \cdot 10^{-8}$
$K_{inhib2}[M]$	$5.0 \cdot 10^{-7}$	$5.0 \cdot 10^{-5}$
$k_3[\frac{L}{mol \cdot s}]$	$5.0 \cdot 10^3$	$5.0 \cdot 10^4$

Table 1: Intervals of variability considered for the uncertain model parameters in the context of stochastic model calibration.

375  
 376 implementation of the ARS algorithm (Bolstad and Curran (2016)) for model  
 377 parameter estimation relies upon embedding multiple model simulations based  
 378 on the widely known and tested software PHREEQC (Parkhurst and Appelo  
 379 (2013)) within the procedure outlined in the following. Acceptance-Rejection  
 380 Sampling is designed to draw samples from the posterior density ( $f_{\mathbf{p}|\mathbf{C}}$ ) of the  
 381 considered random parameter set, conditional on observations of a given target  
 382 quantity. Such a density is proportional to the likelihood function  $f_{\mathbf{C}|\mathbf{p}}$ , which  
 383 is taken to be multi-Gaussian, available data being associated with independent

Parameter	Value
$r_{max1}$ [ $\frac{mM}{d}$ ]	19
$r_{max2}$ [ $\frac{mM}{d}$ ]	11
$K_{half1}^{C_{ORG}}$ [ $M$ ]	$1.6 \cdot 10^{-1}$
$K_{half2}^{C_{ORG}}$ [ $M$ ]	$1.8 \cdot 10^{-2}$
$K_{half}^{NO_3^-}$ [ $M$ ]	$1.0 \cdot 10^{-4}$
$K_{half}^{NO_2^-}$ [ $M$ ]	$5.0 \cdot 10^{-4}$
$K_{inhib}$ [ $M$ ]	$1.0 \cdot 10^{-4}$
$\{CH_2O(s)\}$ [ $mM$ ]	1

Table 2: Model parameters which are considered as fixed from prior studies (Rodríguez-Escales and Sanchez-Vila (2016)).

$t[d]$	$C^{*}$			
	$\frac{\{Dcf\}}{\{Dcf\}_0}$	$\frac{\{C_{ORG}\}}{\{C_{ORG0}\}}$	$\frac{\{NO_2\}}{\{N(V)_0\}}$	$\frac{\{NO_3\}}{\{N(V)_0\}}$
1.55	94.5%	—	—	—
3	70%	57%	49%	45%
5	56%	34%	63%	11%
10	91%	17%	0%	0%
20	83%	—	—	—

Table 3: Available observations for chemical species concentrations. Values are normalized by the initial concentration of the corresponding *master* species ( $\{Dcf\}$  denotes total Diclofenac concentration, including both its anionic and undissociated forms.)

384 errors characterized by a variance  $\sigma_{OBS}^2$ .

385 ARS enables one to draw random samples from  $f_{\mathbf{p}|\mathbf{C}}$  according to the following  
386 workflow:

- 387 (1) Sample  $nmc$  random combinations of the seven uncertain model parameters  
388 from the corresponding uniform priors whose supports are listed in Table 1;
- 389 (2) Evaluate the temporal evolution of the concentrations of the compounds of  
390 interest (i.e., Dcf, organic Carbon, Nitrate and Nitrite) through the geo-  
391 chemical model for each of the  $nmc$  parameter combinations;
- 392 (3) Compute  $nmc$  acceptance probabilities  $\alpha_i$ ,  $i = 1, 2, \dots, nmc$  according to:

$$\begin{aligned} 393 \alpha_i &= \frac{f_{\mathbf{C}|\mathbf{p}_i}}{\max(f_{\mathbf{C}|\mathbf{p}_i})} \\ 394 &= \exp\left(-\frac{1}{2\sigma_{OBS}^2} [\mathbf{C}_i^* - \mathbf{C}_i]^T [\mathbf{C}_i^* - \mathbf{C}_i]\right) \end{aligned} \quad (26)$$

396 where  $N^*$  is the total number of available observations;  $C_i(t)$  is the model-  
397 based concentration of species  $i$  at time  $t$ , normalized by its initial con-  
398 centration;  $\mathbf{p}$  is a vector whose entries correspond to the (seven) uncertain  
399 model parameters, and  $C_i^*$  are the observed data.

- 400
- 401 (4) Draw  $nmc$  random values  $u_i$  ( $i = 1, 2, \dots, nmc$ ) from a uniform  $pdf$  in the  
402 unit support;
- 403 (5) Accept a given model realization  $i$  if the corresponding sampled value of  $u_i$   
404 is smaller than  $\alpha_i$ .

405 The number of Monte Carlo simulations should be designed to guarantee that  
406 stable posterior  $pdfs$  of model parameters are obtained. We note that the rate  
407 of acceptance associated with the algorithm depends on  $\sigma_{OBS}^2$ , whose precise  
408 assessment is clearly affected by quality and quantity of available information.  
409 While large values of  $\sigma_{OBS}^2$  typically lead to a large number of accepted realiza-  
410 tions, these are also related to lower data quality. Since no precise information  
411 about measurement uncertainty is available for the data-set analyzed, we select  
412  $\sigma_{OBS}^2$  as a generally reasonable compromise between a good acceptance rate  
413 and the loss of quality of the data (see also Section 3).

### 414 3. Results and Discussion

415 We present here the results of our study and provide a quantitative analy-  
416 sis of our modeling framework for the characterization of Diclofenac reversible  
417 biodegradation pathway.

418 Following the procedure detailed in Section 2.2, Acceptance-Rejection Sampling  
419 is performed upon setting  $\sigma_{OBS}^2 \approx 0.018$ , as result of a compromise between  
420 achieving a good acceptance rate and considering data which are not associ-  
421 ated with marked loss of quality, the total number of realizations considered  
422 in the ARS approach being set to  $nmc = 200000$ , yielding a number of ac-  
423 cepted realizations in the order of  $10^2$  (details not shown). Figure 3 depicts  
424 the marginal distributions obtained for the seven considered model parameters  
425 conditional on the available observations. For completeness, the prior (uniform)  
426 densities (see Table 1) associated with each model parameters are juxtaposed  
427 to the ARS-based inverse modeling results. The resulting posterior means and  
428 intervals (centered around the mean) of width equal to a standard deviation  
429 are highlighted through vertical, dashed lines. Analysis of these results suggests  
430 that the posterior *pdf* of  $k_1$  is the one which is most affected by conditioning  
431 as it markedly differs from its corresponding prior *pdf*. Conditioning on data  
432 is seen to affect also the *pdfs* of  $k_2$  and  $k_3$ . All of these posterior densities  
433 display well defined peaks, corresponding to the Maximum A Posteriori (MAP)  
434 estimate, the latter being equal to the mode of the posterior distribution (iden-  
435 tified by vertical dashed blue lines in Figure 3). While the posterior marginals  
436 of  $k_1$  and  $k_2$  are nearly symmetric, with modes very close to the correspond-  
437 ing mean values, the distribution of  $k_3$  is visibly left-skewed, conditioning on  
438 data favoring the largest values of this parameter. As a consequence, stochastic  
439 calibration indicates that the back transformation steps (in Phase (III)) tends  
440 to take place with the fastest rates among those analyzed. These features are  
441 reinforced by the analysis of the corresponding box-plots depicted in Figure 4.  
442 The latter results yield a visual appraisal of the width of credible intervals of  
443 the model parameters, here associated with one inter-quartile range (i.e., in-

444 cluded within the first and the third quartiles) of the distributions of  $k_1$ ,  $k_2$ ,  
445 and  $k_3$  and the relative location of the Maximum A Posteriori estimates within  
446 the corresponding prior supports. Figures 3 and 4 evidence the significant re-  
447 duction of the support of the posterior distribution of  $k_1$  with respect to the  
448 corresponding assumed prior. This is consistent with the observation that con-  
449 ditioning on data through (stochastic) inverse modeling yields a reduction of  
450 the uncertainty which is associated with all relevant model parameters in the  
451 absence of measurements. For example, one can note that conditioning on data  
452 leads to a reduction of the prior variance of  $k_1$  by approximately 88%, thus  
453 providing a quantitative metric to support the strong influence of conditioning  
454 on the assessment of this parameter. Variances of  $k_2$  and  $k_3$  are seen to drop by  
455 about 34 and 8%, respectively, as compared against their prior counterparts.  
456 Otherwise, prior and posterior distributions of the remaining four model param-  
457 eters display negligible differences. This is indicative of how no particular value  
458 of these parameters can be identified as most likely to interpret the available  
459 data. The latter is typically considered as an indication that such param-  
460 eters are not influential to the overall variability of the model output following  
461 conditioning to the available observation. As such, any of the values of these  
462 parameters comprised within their range of variability is characterized by the  
463 same likelihood of being consistent with the data considered. Therefore, one  
464 should not expect significant uncertainty reduction for these parameters fol-  
465 lowing acquisition of the type of data here considered. Notice that three of  
466 these parameters are associated with half-saturation and inhibition constants  
467 appearing in *Michaelis-Menten-Monod* kinetics. This result is consistent with  
468 the fact that observed concentrations attain low values, thus explaining why  
469 half-saturation and inhibition constants do not play a major role on the kinetic  
470 processes represented by reaction (13). As an example of the quality of the re-  
471 sults, Figure 5 depicts outputs associated with the proposed geochemical model.  
472 Here, consistent with the stochastic model calibration framework,  $k_1$ ,  $k_2$ , and  $k_3$   
473 are set at their MAP, while the remaining model parameters are characterized  
474 through their corresponding average value. These results are complemented




Figure 3: Prior and posterior *pdfs* of the model parameters, together with MAP estimates (dashed blue lines), mean values (dashed red lines). Dashed green lines delineate intervals of width equal to twice the standard deviation and centered around the corresponding mean value.




Figure 4: Boxplot representation of the marginal distributions of parameter values resulting from the inverse modeling procedure. Blue circles correspond to MAP estimates, red squares denoting lower and upper limits of the support of the prior distributions.

475 by Table 4 where we list parameter values associated with modeling results of  
 476 Figure 5. One can see that considering MAP estimates of model parameters  
 477 is conducive to high quality estimates of the fate of Diclofenac, even as it is  
 478 evident that the MAP-based geochemical model tends to slightly underestimate  
 479 the reaction progresses along the depicted temporal window. A good agreement  
 480 is still observed amongst model- and observation-based concentrations for most  
 481 of the main compounds undergoing redox reactions along the Nitrogen reduc-  
 482 tion path (Figure 5a). A non-negligible discrepancy is otherwise observed with  
 483 reference to the temporal trend of organic Carbon degradation, our modeling re-  
 484 sults clearly underestimating the associated consumption rate. The latter result  
 485 is consistent with (a) the observation that the temporal evolution of biomass  
 486 concentration in the system has been neglected due to the limited dataset avail-  
 487 able, which prevents reliance on a more complex modeling approach; and (b)  
 488 the study of Barbieri et al. (2012) who derive similar conclusions about the  
 489 fate of organic matter along the biodegradation pathway. Indeed, these authors  
 490 highlight that a relevant percentage (around 27%) of organic Carbon is possi-



491 bly consumed due to the action of additional processes, which are not included  
492 in their geochemical model. On these bases, and in line with Barbieri et al.  
493 (2012), an additional contribution of about  $2.2[mM]$  to the net consumption of  
494 organic Carbon is expected due to its further degradation as substrate that sus-  
495 tains bacterial growth (additional details on associated biochemistry are offered  
496 in the Supplementary Material S1.1.2).

497 As an example of the benefits arising from relying on a stochastic model calibra-  
498 tion, Figure 6 shows the results of uncertainty propagation to the Dcf concentra-  
499 tion history. Figure 6a depicts the temporal behavior of selected percentiles (i.e.,  
500  $5^{th}$ ,  $50^{th}$ , and  $95^{th}$ ) as wells as the mean of the probability distribution of (nor-  
501 malized) Dcf concentrations resulting from our modeling study. Experimental  
502 observations are also depicted as a reference, together with the temporal evo-  
503 lution of Dcf concentrations obtained through the collection of some exemplary  
504 model realizations associated with the posterior probability densities of model  
505 parameters (solid grey curves). Figure 6b completes the picture upon showing  
506 *pdfs* of Dcf concentrations conditional on available data at three selected ob-  
507 servation times. The width of the intervals associated with values comprised  
508 between the  $5^{th}$  and  $95^{th}$  percentile of the distribution widely vary across the  
509 temporal window considered, attaining a seemingly stable value at late time.  
510 The latter feature is consistent with our expectations, as our model does not  
511 implement any additional process downstream of the back-transformation to the  
512 parent compound, which is expected to end significantly sooner than the last  
513 monitored time (20 days).

514 The available measurements are well within the intervals delineated by the (pos-  
515 terior)  $5^{th}$  and  $95^{th}$  percentiles. An exception is noted at early times (i.e.,  $t = 3$   
516 days), with reference to a possible under-estimation of the nitrosation rate of  
517 HDcf, consistent with the trend outlined in Figure 5. This might be indicative  
518 of faster nitrosation rates than those associated with our model, whose results  
519 are otherwise fully consistent with the other available data. Finally, we observe  
520 that the initial decrease and successive increase of Dcf concentration tend to  
521 attain a similar rate, i.e. concentration histories attain a roughly symmetric U-

522 shape around time 5 – 6 days. In particular, the steep increase of Dcf observed  
 523 at time 7 – 8 days for certain realizations (Figure 6a) can be linked with the  
 524 relatively high probability of observing large values of the back-transformation  
 525 rate constant  $k_3$  (see Figure 3).

526 Our probabilistic results can then assist to assess the uncertainty linked to  
 527 model outputs of interest also at unsampled times. In this context, exemplary  
 528 probability density functions of Dcf are depicted in Figure 6c at unsampled  
 529 times. The ability to have at our disposal these types of results is critical to  
 530 support, for example, probabilistic risk assessment under uncertainty where one  
 531 can be interested in quantifying the probability of exceeding a given threshold  
 532 concentration in time. For example, these results suggest that posterior densi-  
 533 ties tend to almost overlap at sufficiently late times (such as, e.g.,  $t = 18$  and  
 534  $t = 21$  days). Notice that this behavior is consistent with our expectations, as  
 535 Diclofenac concentrations are not expected to undergo further variations after  
 536 completion of back-transformation processes (denoted as Phase (III) in Section  
 2.1.1).

Parameter type	Parameter value	$\text{Log}_{10}$ of Parameter value
$k_1[\frac{L^2}{mol^2.s}]$	8.7096E+08	8.94
$k_2[\frac{L^{0.4}}{mol^{0.4}.s}]$	1.4791E+03	3.17
$r_{max3}[\frac{1}{s}]$	8.0E-11	-10.1
$K_{half3}^{C_{ORG}}[M]$	1.2E-06	-5.9
$K_{half}^{NO_2Dcf}[M]$	7.9E-10	-9.1
$K_{inhib2}[M]$	5.0E-06	-5.3
$k_3[\frac{L}{mol.s}]$	2.9854e+05	5.47

Table 4: Estimated model parameters:  $k_1$ ,  $k_2$ , and  $k_3$  values correspond to MAP estimates, whereas the remaining model parameters are estimated through the corresponding empirical posterior mean value.

537




Figure 5: Normalized concentrations of the main species involved along (a) the Nitrogen reduction cycle and (b) the Diclofenac reversible transformation pathway. Results are obtained employing the calibrated model, where the most influential parameters ( $k_1$ ,  $k_2$ , and  $k_3$ ) are set to corresponding MAP values, whereas the remaining ones ( $r_{max3}$ ,  $K_{half3}^{C_{ORG}}$ ,  $K_{half}^{NO_2Dcf}$ , and  $K_{inhib2}$ ) are set to their posterior means. Available measurements are highlighted with diamonds. Percentage differences between Diclofenac observations ( $C^*$ ) and modeling results ( $C$ ) are also included.

#### 538 4. Conclusions

539 Diclofenac (Dcf) is often detected in water resources and groundwater bod-  
 540 dies and is increasingly recognized as a threat for the delicate balance of aquatic  
 541 ecosystems, especially in view of its bioactive nature and recalcitrance. Our  
 542 study provides a model and the associated operational workflow aimed at as-  
 543 sisting the assessment of the fate of Diclofenac under uncertainty at relevant  
 544 environmental conditions. The model rests on a detailed description of the  
 545 molecular mechanisms associated with the biotransformation pathway of Di-  
 546 clofenac and is framed within a stochastic context that enables obtaining a  
 547 probability distributions of target quantities conditional to available observa-  
 548 tions. We demonstrate our approach through a set of available laboratory-scale  
 549 data (Barbieri et al. (2012)). Our work leads to the following major conclu-  
 550 sions.

- 551 • Our process-based biochemical model enables us to interpret the reversible  
 552 pathway exhibited by Dcf in the context of the analyzed laboratory ex-





Figure 6: (a) Temporal evolution of Diclofenac concentrations obtained through a collection of exemplary model realizations associated with the posterior probability densities of model parameters (solid grey curves) together with the corresponding mean (solid blue), percentiles  $P_{0.05}$ , dashed green,  $P_{0.5}$ , dashed blue, and  $P_{0.95}$ , dashed red, and experimental observations (diamonds); (b) Diclofenac concentration pdfs at selected observation times together with the corresponding sampled values (vertical dashed lines); (c) Diclofenac concentration pdfs at selected unsampled times.

553 periments. Our conceptual model considers three subsequent phases of  
554 Dcf biotransformation, ultimately leading to the recovery of the parent  
555 compound in dissolved phase. The model couples Dcf biotransformation  
556 to the nitrogen cycle. The documented ineffectiveness of Dcf degrada-  
557 tion under the experimental conditions investigated in this study possibly  
558 suggests the opportunity to explore diverse biodegradation pathways in  
559 future research, such as, e.g., settings associated with stronger oxidizers,  
560 eventually leading to complete mineralization of the original molecule.

- 561 • We describe selected model parameters by way of their (posterior, i.e.,  
562 conditional on available data) probability distribution upon relying on an  
563 acceptance-rejection sampling algorithm. An optimal parameter combi-  
564 nation is identified through the ensuing Maximum A Posteriori (MAP)  
565 estimates of model parameters. Relying on MAP parameter estimates  
566 yields a good agreement between model results and observations, relative  
567 residuals associated with Dcf concentrations being always smaller than  
568 15%. Our model is seen to underestimate organic Carbon concentration,  
569 this being likely due to the fact that biomass dynamics are here neglected.
- 570 • Our results suggest that experimental observations of the kind considered  
571 here might not be exhaustive to yield sharp estimates of all of the biochem-  
572 ical parameters potentially affecting Dcf biotransformation. Posterior dis-  
573 tributions associated with kinetic rates exhibit a unique peak, suggesting  
574 that optimal parameter values could be identified (in a stochastic inverse  
575 modeling context). Otherwise, the available data do not lead to a reduc-  
576 tion of the uncertainty related to half-saturation and inhibition constants,  
577 their prior and posterior distributions being not too dissimilar. This result  
578 is likely linked to the low concentrations exhibited by the Dcf in the con-  
579 sidered experiment, and implies that the available data do not enable one  
580 to constrain the probability distribution of inhibition and half-saturation  
581 constants associated with the *Michaelis-Menten-Monod* rates. Our anal-  
582 ysis provides an example of the usefulness of a probabilistic framework to

583 identify residual model parameter uncertainty following conditioning on  
584 observations.

585 • Probability distributions of Dcf concentrations are obtained by propagat-  
586 ing the obtained posterior *pdfs* of input parameters through the considered  
587 model. At sufficiently long times the *pdfs* associated with Dcf concentra-  
588 tion values are left-skewed with a peak corresponding to a 90-100% recov-  
589 ery of the initial concentration. With reference to the Dcf concentrations  
590 increase, our results suggest that the back-transformation step is charac-  
591 terized by a fast kinetic behavior, leading to sharp variations of the Dcf  
592 with time.

### 593 **Acknowledgements**

594 This work was funded by *Bracco Imaging* (Italy).

595 **Appendix A. Chemical structure of parent compound and transfor-**  
596 **mation products**

597 In this Section, we provide structural formulas for the main chemical species  
involved in the reactive processes of Diclofenac reversible pathway.




Figure A.1: Parent compound and products of its dissolution and aqueous speciation: (a) Sodium Diclofenac (NaDcf), (b) Diclofenac acid (HDcf) and (c) Diclofenac anion (Dcf<sup>-</sup>).

598




Figure A.2: Main transformation products of Diclofenac: (a) N-Nitroso-Dcf, (b) 5-Nitro-Dcf (para isomer) and (c) 5-Aminyl-Dcf (para isomer).




Figure A.3: Intermediates appearing in Phase (II) of the pathway: (a) Nitroso radical cation (NODcf<sup>+•</sup>), (b) unstable canonical form of resonance (nitrenium cation) of Dcf<sup>+</sup> and (c) main canonical form of resonance (carbocation) of Dcf<sup>+</sup>.






Figure A.4: Intermediates appearing in Phase (II) of the pathway: (a) the second structural isomer of the nitro-derivative ( $\text{NO}_2\text{Dcf}_{\text{ISO}_2}$ ) and (b) 5-Nitro-Diclofenac ( $\text{NO}_2\text{Dcf}$ ).




Figure A.5: Chemical species appearing during back-transformation reactions: (a) intermediate carbocation ( $\text{NH}_3\text{Dcf}^+$ ) and (b) Hydroxylamine ( $\text{NH}_2\text{OH}$ ).



599 **References**

- 600 Appelo, C.A.J., Postma, D., 2004. *Geochemistry, groundwater and pollution*.  
601 CRC press.
- 602 Barbieri, M., Carrera, J., Sanchez-Vila, X., Ayora, C., Cama, J., Köck-  
603 Schulmeyer, M., de Alda, M.L., Barceló, D., Brunet, J.T., García, M.H., 2011.  
604 Microcosm experiments to control anaerobic redox conditions when studying  
605 the fate of organic micropollutants in aquifer material. *Journal of Contami-*  
606 *nant Hydrology* 126, 330–345.
- 607 Barbieri, M., Carrera, J., Ayora, C., Sanchez-Vila, X., Licha, T., Nödler, K.,  
608 Osorio, V., Pérez, S., Köck-Schulmeyer, M., de Alda, M.L., et al., 2012. For-  
609 mation of diclofenac and sulfamethoxazole reversible transformation products  
610 in aquifer material under denitrifying conditions: batch experiments. *Science*  
611 *of the Total Environment* 426, 256–263.
- 612 Bolstad, W.M., Curran, J.M., 2016. *Introduction to Bayesian statistics*. John  
613 Wiley & Sons.
- 614 Committee for Medicinal Products for Human Use (CHMP), E.M.A., 2006.  
615 Guideline on the environmental risk assessment of medicinal products for  
616 human use. EMEA/CHMP/SWP/4447/00 corr 1.
- 617 Chiron, S., Duwig, C., 2016. Biotic nitrosation of diclofenac in a soil aquifer  
618 system (katari watershed, bolivia). *Science of the Total Environment* 565,  
619 473–480.
- 620 de Voogt, P., Sacher, F., Janex-Habibi, M.L., Puijker, L., Mons, M., 2007.  
621 Development of an international priority list of pharmaceuticals relevant for  
622 the water cycle. *Water science and technology: a journal of the International*  
623 *Association on Water Pollution Research* 59(1), 39–46.
- 624 Fonger, G.C., Hakkinen, P., Jordan, S., Publicker, S., 2014. The national library  
625 of medicine’s (nlm) hazardous substances data bank (hsdb): background,  
626 recent enhancements and future plans. *Toxicology* 325, 209–216.

- 627 Greskowiak, J., Hamann, E., Burke, V., Massmann, G., 2017. The uncertainty  
628 of biodegradation rate constants of emerging organic compounds in soil and  
629 groundwater – a compilation of literature values for 82 substances. *Water*  
630 *Research* 126, 122–133.
- 631 Kulkarni, M., Chaudhari, A., 2007. Microbial remediation of nitro-aromatic  
632 compounds: an overview. *Journal of Environmental Management* 85, 496–  
633 512.
- 634 Lonappan, L., Brar, S.K., Das, R.K., Verma, M., Surampalli, R.Y., 2016. Di-  
635 clofenac and its transformation products: environmental occurrence and tox-  
636 icity – a review. *Environment International* 96, 127–138.
- 637 Mirvish, S.S., 1975. Formation of n-nitroso compounds: chemistry, kinetics, and  
638 in vivo occurrence. *Toxicology and applied pharmacology* 31, 325–351.
- 639 Nham, H.T.T., Greskowiak, J., Nödler, K., Rahman, M.A., Spachos, T., Ruste-  
640 berg, B., Massmann, G., Sauter, M., Licha, T., 2015. Modeling the transport  
641 behavior of 16 emerging organic contaminants during soil aquifer treatment.  
642 *Science of the Total Environment* 514, 450–458.
- 643 Parkhurst, D.L., Appelo, C., 2013. Description of input and examples for  
644 PHREEQC version 3: a computer program for speciation, batch-reaction,  
645 one-dimensional transport, and inverse geochemical calculations. Technical  
646 Report. US Geological Survey.
- 647 Porta, G., la Cecilia, D., Guadagnini, A., Maggi, F., 2018. Implications of  
648 uncertain bioreactive parameters on a complex reaction network of atrazine  
649 biodegradation in soil. *Advances in Water Resources* 121, 263–276.
- 650 Razo-Flores, E., Donlon, B., Lettinga, G., Field, J.A., 1997. Biotransforma-  
651 tion and biodegradation of n-substituted aromatics in methanogenic granular  
652 sludge. *FEMS microbiology reviews* 20, 525–538.

- 653 Rodríguez-Escales, P., Sanchez-Vila, X., 2016. Fate of sulfamethoxazole in  
654 groundwater: Conceptualizing and modeling metabolite formation under dif-  
655 ferent redox conditions. *Water Research* 105, 540–550.
- 656 Schaffer, M., Kröger, K.F., Nödler, K., Ayora, C., Carrera, J., Hernández, M.,  
657 Licha, T., 2015. Influence of a compost layer on the attenuation of 28 selected  
658 organic micropollutants under realistic soil aquifer treatment conditions: In-  
659 sights from a large scale column experiment. *Water Research* 74, 110–121.
- 660 Small, R., 1989. Diclofenac sodium. *Clinical pharmacy* 8, 545–558.
- 661 Smith, M.B., 2020. *March’s advanced organic chemistry: reactions, mechanisms,*  
662 *and structure.* John Wiley & Sons.
- 663 Sobol, I.M., 1998. On quasi-monte carlo integrations. *Mathematics and com-*  
664 *puters in simulation* 47, 103–112.
- 665 Stumm, W., Morgan, J.J., 2012. *Aquatic chemistry: chemical equilibria and*  
666 *rates in natural waters.* volume 126. John Wiley & Sons.
- 667 Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard,  
668 P., Chang, Z., Woolsey, J., 2006. Drugbank: a comprehensive resource for in  
669 silico drug discovery and exploration. *Nucleic acids research* 34, D668–D672.



Click here to access/download

**Electronic Supplementary Material (for online publication  
only)**

SupplementaryMaterialsIndex.docx



Click here to access/download

**Electronic Supplementary Material (for online publication  
only)**

S1\_Detailedhydrogeochemistry\_phreeqcimplementation.  
tex



Click here to access/download

**Electronic Supplementary Material (for online publication  
only)**


S2\_Experimental\_framework.tex



# Graphical Abstract

## Formulation and probabilistic assessment of reversible biodegradation pathway of Diclofenac in groundwater

### Geochemical model



### Results in a stochastic Bayesian framework


Diclofenac concentrations =  $f(k_1, k_2, r_{max3}, K_{half3}^{CORG}, K_{half}^{NO_2Dcf}, K_{inhib2}, k_3)$

Outputs

Model

Parameters

#### Percentiles of model outputs



#### Estimated parameters and associated uncertainty





Figure 1





Figure 2

## DICLOFENAC REVERSIBLE BIODEGRADATION PATHWAY



### ***Equilibrium driven reactions:***

**$R_1$** : Diclofenac precipitation / dissolution  
 **$R_2^{(i)}$** : Acid dissociation / aqueous complexation of *i*-th compound  
 **$R_3$** : Diclofenac adsorption due to surface complexation

### ***Kinetic reactions:***

**$R_4$** : Diclofenac N-nitrosation by co-metabolism  
 **$R_5$** : Nitroso to Nitro-Diclofenac evolution  
 **$R_7$** : Electrophilic Aromatic Substitution

### ***Kinetic biotransformation reactions (Michaelis-Menten-Monod):***

**$R_6$** : Nitro to Aminyl-Diclofenac reduction by direct metabolism  
 **$R_8$** : Reduction N(V) to N(III)  
 **$R_9$** : Reduction N(III) to N(0)  
 **$P_1$** : Organic carbon C(-0.8) oxidation to C(IV): first path  
 **$P_2$** : Organic carbon C(-0.8) oxidation to C(IV): second path  
 **$P_3$** : Organic carbon C(-0.8) oxidation to C(IV): third path